![free age progression free age progression](https://image.shutterstock.com/image-photo/aging-260nw-584127133.jpg)
#FREE AGE PROGRESSION TRIAL#
The DESTINY-Breast 03 trial included 524 patients randomized to either the T-DXd group or the comparator T-DM1 group. Looking at new therapies, they have significantly more progression-free survival compared to T-DM1.
![free age progression free age progression](https://techreviewpro-techreviewpro.netdna-ssl.com/wp-content/uploads/2017/12/Oldify-age-progression-app.jpg)
“In the last eight years, I haven’t seen other therapies try to beat it in direct trials. It has a solid safety and efficacy profile,” said David Geffen School, a medical professor. “T-DM1 became the second-line standard of care in 2013 and is the first FDA-approved antibody-drug conjugate. The results of a newly reported clinical trial called DESTINY-Breast 03 show that T-DXd is significantly superior to T-DM1 when used after the patient’s disease has progressed with trastuzumab and chemotherapy. This approval was based on DESTINY-Breast 01, a smaller non-comparative trial that showed very promising efficacy in patients with advanced disease after T-DM1. A HER2-based regimen in a metastatic setting. T-DXd received accelerated approval from the US Food and Drug Administration in 2019 for patients with unresectable or metastatic HER2-positive breast cancer who received two or more doses of anticancer drugs. Promising new drugs have emerged as effective options for these patients. However, the vast majority of patients with advanced disease experience disease resistance and progression despite receiving these targeted therapies. The development of HER2-targeted therapies such as trastuzumab, pertuzumab, and T-DM1 has significantly improved outcomes such as survival associated with the disease. That is, the tumor has an extra copy of the HER2 gene and too much HER2 protein on the cell surface, causing the cancer to behave more aggressively, leading to the following adverse consequences: High probability of metastasis or spread throughout the body. Up to 20% of breast cancers are classified as HER2-positive.